Plasma Homocysteine and l-DOPA Metabolism in Patients with Parkinson Disease
Authors:
Open Access
- 1 June 2001
- journal article
- letter
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 47 (6) , 1102-1104
Abstract
Homocysteine is formed by demethylation of methionine and is involved in transmethylation mechanisms. Hyperhomocysteinemia is associated with a wide range of clinical manifestations, mostly affecting the central nervous system (e.g., mental retardation, cerebral atrophy, and epileptic seizures) (1)(2). Hyperhomocysteinemia has also been associated with an increased risk for atherosclerotic and thrombotic vascular diseases (3)(4)(5). Although various mechanisms have been proposed, mostly involving endothelial damage related to increased oxidative stress (6), the exact cellular and molecular bases for the adverse effects of homocysteine are still elusive.Keywords
This publication has 21 references indexed in Scilit:
- Elevated Plasma Levels of Homocysteine inParkinson’s DiseaseEuropean Neurology, 1998
- Effect of L-Dopa and the Catechol-O-Methyltransferase Inhibitor Ro 41–0960 on Sulfur Amino Acid Metabolites in RatsClinical Neuropharmacology, 1997
- Oxidative stress and the pathogenesis of Parkinson's diseaseNeurology, 1996
- Homocysteine mediated endothelial cell toxicity and its ameliorationAtherosclerosis, 1996
- Hyperhomocysteinaemia; with reference to its neuroradiological aspectsNeuroradiology, 1995
- Decreased methionine adenosyltransferase activity in erythrocytes of patients with dementia disordersEuropean Neuropsychopharmacology, 1995
- Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidantsBrain Research, 1995
- The effects of L-dopa on the activity of methionine adenosyltransferase: Relevance to L-dopa therapy and toleranceNeurochemical Research, 1993
- Stroke and Parkinson's disease.Stroke, 1992
- Functional methionine synthase deficiency (cblE and cblG): Clinical and biochemical heterogeneityAmerican Journal of Medical Genetics, 1989